Evofem Biosciences issues $769K convertible notes and warrants for ~$490K net

Evofem Biosciences, Inc.

Aggregate $769,230.76 in senior subordinate convertible notes issued to investors.
Warrants to purchase 76,923,077 shares of common stock issued.
Investors paid $650 per $1,000 principal amount (~35% discount).
Net proceeds to company after expenses approximately $490,000.
Offering closed April 5, 2023; this 8-K/A corrects a typo in the original report.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $769,230.76 (effective 2023-04-05).

Action: entry
Agreement: notes offering
Counterparty: certain investors
Value: $769,230.76
Effective: 2023-04-05

Exact text from the filing

On April 5, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”) entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $769,230.76

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-011892

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.